<html>
        <head>
            <link rel="stylesheet" type="text/css" href="layout.css" />
        </head>
        <style> 
            .right { 
                margin-left: 160px;
            } 
        </style>
        
        <div class="sidenav">
            <a href="#">About</a>
            <a href="index_gpt.html">Index</a>
        </div>
    <div class="header"><h3>DAPA-HF</h3></div><p><span class="main">"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction". </span></p><p><span class="contents">
                                        Links to original sources:
                                        <a href=https://www.wikijournalclub.org//wiki/DAPA-HF>Wiki Journal Post</a>
                                        <a href=http://www.nejm.org/doi/full/10.1056/NEJMoa1911303>Full Journal Article</a>
                                        </span></p><p><span class="main">The New England Journal of Medicine. 2019.
 </span></p><p><span class="main">PubMed • Full text • PDF
 </span></p><p><span class="main">Contents
 </span></p><p><span class="main">1 Clinical Question
2 Bottom Line
3 Major Points
4 Guidelines
5 Design
6 Population
6.1 Inclusion Criteria
6.2 Exclusion Criteria
6.3 Baseline Characteristics
7 Interventions
8 Outcomes
8.1 Primary Outcomes
8.2 Secondary Outcomes
8.3 Additional Analyses
9 Criticisms
10 Funding
11 Further Reading
 </span></p><h2><span class="labels">Clinical Question</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Does dapagliflozin improve outcomes in patients with heart failure and a reduced ejection fraction regardless of the presence or absence of type 2 diabetes?
 </span></p><h2><span class="labels">Bottom Line</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Among patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin decreased the risk of worsening heart failure or death from cardiovascular causes and improved symptom scores, irrespective of diabetes status.
 </span></p><h2><span class="labels">Major Points</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Previous trials demonstrated that SGLT2 inhibitors can reduce hospitalization for heart failure in type 2 diabetes patients. This trial, the DAPA-HF study, showed a significant benefit of dapagliflozin in heart failure patients with reduced ejection fraction with or without type 2 diabetes.
 </span></p><h2><span class="labels">Guidelines</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">As of the knowledge cutoff date, there have been no updates to guidelines based on this study's findings. Heart failure guidelines may be updated in the future to include SGLT2 inhibitors based on the DAPA-HF results.
 </span></p><h2><span class="labels">Design</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Phase 3, multicenter, double-blind, placebo-controlled randomized trial
N=4744 patients with heart failure and reduced ejection fraction
Intervention: Dapagliflozin (10 mg daily) (n=2373)
Control: Placebo (n=2371)
Median follow-up: 18.2 months
 </span></p><h2><span class="labels">Population</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Inclusion Criteria:
- ≥18 years old
- NYHA class II, III, IV heart failure
- Ejection fraction ≤40%
- Elevated NT-proBNP levels
 </span></p><p><span class="main">Exclusion Criteria:
- Recently treated with or intolerant to SGLT2 inhibitors
- Type 1 diabetes
- Symptoms of hypotension, systolic BP <95 mm Hg
- eGFR <30 ml/min/1.73 m²
 </span></p><p><span class="main">Baseline Characteristics
- Well balanced between groups
- 42% with type 2 diabetes at baseline
 </span></p><h2><span class="labels">Interventions</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Patients were randomized to either dapagliflozin or placebo along with standard heart failure therapy.
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Primary Outcomes:
- Composite of worsening heart failure (hospitalization or urgent visit resulting in IV therapy) or cardiovascular death significantly lower in the dapagliflozin group (16.3% vs. placebo 21.2%; HR, 0.74; P<0.001)
 </span></p><h2><span class="labels">Outcomes</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Improved symptoms based on the Kansas City Cardiomyopathy Questionnaire
- No difference in the composite renal outcome between groups
 </span></p><p><span class="main">Additional Analyses
- Benefit observed early after randomization
- Similar benefits in patients without diabetes
- Few patients discontinued due to adverse effects
 </span></p><h2><span class="labels">Criticisms</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">- Specific inclusion and exclusion criteria may limit generalizability
- Underrepresentation of certain demographics (e.g., black patients, very elderly)
- Low baseline use of sacubitril–valsartan
 </span></p><h2><span class="labels">Funding</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Funded by AstraZeneca.
 </span></p><h2><span class="labels">Further Reading</span></h2> <hr width="88.5%", align = "right", size="2"><p><span class="main">Additional literature relevant to this clinical trial can be found in the Supplementary Appendix provided at NEJM.org. </span></p>    	
        <div class="footer">Footer</div>
        </body>
        </html>